EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Dietary intake remains unchanged while nutritional status improves in children and adults with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor

R Enaud, J Languepin, M Lagarrigue, A Arrouy, J Macey, S Bui, M Dupuis, L Roditis, C Flumian, E Mas, M Mittaine

Clinical Nutrition · 2025

DOI: 10.1016/j.clnu.2025.04.027 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Nutrition, 2025. Verfasst von R Enaud und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Bordeaux, INSERM U1045, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Bordeaux, France; Bordeaux University Hospital, CRCM …. Hauptthemen laut MEDLINE: Cystic Fibrosis, Diet, Nutritional Status, Chloride Channel Agonists. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cystic fibrosis (CF) is a genetic disorder involving multi-organ dysfunction, with nutritional status playing a crucial role in disease progression. Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulator therapy, particularly the combination Elexacaftor/Tezacaftor/Ivacaftor (ETI), has shown numerous clinical benefits, including significant improvements in nutritional status. However, the factors driving this nutritional improvement, especially the potential role of increased dietary intake, remain underexplored. This study aimed to assess changes in nutritional status and dietary intake in patients with CF (pwCF) treated with ETI. METHODS: 62 pwCF (36 children, 26 adults) were analyzed in a prospective, realworld, multicenter study (https://clinicaltrials.gov/study/NCT06072365). Dietary intakes were assessed via 3-day food diaries collected at baseline (M0) and one year after ETI treatment initiation (M12). RESULTS: Over the first year of ETI treatment, Body Mass Index (BMI) significantly increased with a median BMI Z-score gain of 0.2 (IQR: 0.7) for children and median BMI gain of 1.0 kg/m2 (IQR: 1.8) for adults. Notably, these gains occurred without a significant increase in median daily caloric intake (2216 kcal (IQR: 750) at M0 vs. 2266 (IQR: 733) kcal at M12). Pancreatic enzyme requirements and calprotectin decreased significantly with ETI (p < 0.001 and p < 0.01, respectively), indicating improved pancreatic function and intestinal inflammation in some patients. Seven patients became overweight after one year of ETI. CONCLUSION: ETI therapy enhances nutritional status in pwCF, independently of increased caloric intake. Further research is essential to refine dietary recommendations under ETI treatment, aiming to prevent overweight and obesity while optimizing health outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisDietNutritional StatusChloride Channel AgonistsAdolescentAdultChildFemaleHumansMaleYoung AdultAminophenolsBenzodioxolesDrug CombinationsIndolesOxadiazolesProspective StudiesPyrazolesPyridinesQuinolonesQuinolines

Stichwörter der Autor:innen

AdultsCFTR modulatorChildrenCystic fibrosisDietary intakeNutrition

Substanzen

AminophenolsBenzodioxolesDrug CombinationsIndolesOxadiazolesPyrazolesPyridinesQuinoloneselexacaftor, ivacaftor, tezacaftor drug combinationChloride Channel Agonists

Autor:innen und Institutionen

  • University of Bordeaux, INSERM U1045, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Bordeaux, France; Bordeaux University Hospital, CRCM pédiatrique, CIC 1401, Bordeaux, France.
  • Limoges University Hospital, Paediatric Cystic Fibrosis Reference Center (CRCM), Limoges, France.
  • Centre de ressources et de compétences pour la mucoviscidose, Hôpital des Enfants, CHU de Toulouse, Toulouse, France.
  • Centre de ressources et de compétences pour la mucoviscidose, Hôpital des Enfants, CHU de Toulouse, Toulouse, France; Service de Gastroentérologie, Hépatologie, Nutrition et Maladies Héréditaires du Métabolisme, Hôpital…
  • Bordeaux University Hospital, Adult CF center, France.
  • Bordeaux University Hospital, CRCM pédiatrique, CIC 1401, Bordeaux, France.

Zitieren

APA

Enaud, R., Languepin, J., Lagarrigue, M., Arrouy, A., Macey, J., Bui, S., Dupuis, M., Roditis, L., Flumian, C., Mas, E., & Mittaine, M. (2025). Dietary intake remains unchanged while nutritional status improves in children and adults with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor. Clinical Nutrition. https://doi.org/10.1016/j.clnu.2025.04.027

Vancouver

Enaud R, Languepin J, Lagarrigue M, Arrouy A, Macey J, Bui S, et al. Dietary intake remains unchanged while nutritional status improves in children and adults with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor. Clinical Nutrition. 2025. doi:10.1016/j.clnu.2025.04.027

BibTeX
@article{Enaud2025,
  author = {Enaud, R and Languepin, J and Lagarrigue, M and Arrouy, A and Macey, J and Bui, S and Dupuis, M and Roditis, L and Flumian, C and Mas, E and Mittaine, M},
  title = {Dietary intake remains unchanged while nutritional status improves in children and adults with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor},
  journal = {Clinical Nutrition},
  year = {2025},
  doi = {10.1016/j.clnu.2025.04.027}
}
Kostenlos starten →